DV
Dividend Vision

AKBA — Akebia Ther

Akebia Ther (AKBA)

Total return is -96.7% over the past 12.4 years, 507.1 points behind SPY at 410.4%. Its deepest 1-year drawdown was 74.4%.

Akebia Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for kidney disease patients. The company's marketed products include Vafseo (vadadustat) for anemia in chronic kidney disease and Auryxia (ferric citrate) for phosphorus control and iron deficiency anemia, alongside pipeline candidates in clinical development. Akebia does not currently distribute dividends.

AKBA key facts

Asset type
Stock
Asset class
Equity
Inception date
03/20/2014
Last close
$0.87
Market cap
$359,466,048
Average volume
2086500.0
Beta
0.235
Payout ratio
0.0
Forward P/E
28.7356
EPS
$-0.08